Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Anticancer Research

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  PMID 27272791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer?

  2015cited by this paper
• Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status

  2015cited by this paper
• Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.

  2015cited by this paper
• Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.

  2013cited by this paper
• The SPECTRUM of findings in treatment options for recurrent/metastatic head and neck cancer.

  2013cited by this paper
• Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

  2013cited by this paper
• Potentially Novel Candidate Biomarkers for Head and Neck Squamous Cell Carcinoma Identified Using an Integrated Cell Line-based Discovery Strategy*

  2012cited by this paper
• Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma.

  2012cited by this paper
• Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.

  2012cited by this paper
• EGFR Kinase Promotes Acquisition of Stem Cell-Like Properties: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma Stem Cells

  2012cited by this paper
• The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms?

  2011cited by this paper
• The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

  2011cited by this paper
• Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.

  2011cited by this paper
• Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

  2010cited by this paper
• Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures.

  2010cited by this paper
• New Developments in Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed Chronic Myeloid Leukemia

  2010cited by this paper
• Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma.

  2009cited by this paper
• Expression of Vascular Endothelial Growth Factor and Hypoxia Inducible Factor‐1α in Cervical Neoplasia

  2009cited by this paper
• Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.

  2009cited by this paper
• Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

  2009cited by this paper
• Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

  2009cited by this paper
• Human papillomavirus frequency in oral and oropharyngeal cancer in Greece.

  2008cited by this paper
• The history of the angiogenic switch concept

  2007cited by this paper
• Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.

  2007cited by this paper
• Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

  2007cited by this paper
• Erlotinib in non-small cell lung cancer treatment: current status and future development.

  2007cited by this paper
• Erlotinib in cancer treatment.

  2007cited by this paper
• Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic Switch

  2006cited by this paper
• Epidermal growth factor receptor biology in head and neck cancer.

  2006cited by this paper
• Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

  2006cited by this paper
• Inhibitors of growth factor signalling.

  2005cited by this paper
• VEGF as a Therapeutic Target in Cancer

  2005cited by this paper
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.

  2004cited by this paper
• The interplay between Src family kinases and receptor tyrosine kinases

  2004cited by this paper
• Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors

  2004cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

  2002cited by this paper
• Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.

  2001cited by this paper
• Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner

  2000cited by this paper
• Vascular endothelial growth factor and the regulation of angiogenesis.

  2000cited by this paper
• From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

  2000cited by this paper
• HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes.

  1999cited by this paper
• Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

  1999cited by this paper
• Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor.

  1994cited by this paper

• Precision therapeutic targets for HPV-positive cancers: an overview and new insights

  2025cites this paper
• Improving Outcomes in Oral Cancer: A Clinical and Translational Update

  2020cites this paper
• RTKs in pathobiology of head and neck cancers.

  2020cites this paper
• Investigational multitargeted kinase inhibitors in development for head and neck neoplasms

  2019cites this paper
• Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer

  2019cites this paper
• Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.

  2018cites this paper
• Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

  2018cites this paper
• HIF-1α and mTOR - Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC.

  2018cites this paper
• Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro.

  2017cites this paper
• Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.

  2017cites this paper